10-K: Dentsply Sirona Reports $598M Loss, Cuts Dividend Amid Sales Decline

Dentsply Sirona reported a significant net loss of $598 million for 2025, a 3.0% decrease in net sales, and eliminated its quarterly dividend, signaling ongoing operational and financial challenges.

Summary

• Net sales for the year ended December 31, 2025, decreased by 3.0% (4.3% on a constant currency basis) compared to the prior year, totaling $3,680 million.
• The company reported a net loss of $598 million for 2025, an improvement from the $910 million net loss in 2024, primarily due to lower goodwill and intangible asset impairment charges.
• Diluted loss per share was $3.00 in 2025, compared to $4.48 in 2024.
• Cash flow from operations significantly decreased to $235 million in 2025 from $461 million in 2024.
• Goodwill and intangible asset impairment charges totaled $650 million in 2025, down from $1,014 million in 2024.
• The Board of Directors eliminated the declaration of quarterly dividends on common stock starting in the quarter ending March 31, 2026.
• A new restructuring plan (the 2026 Plan) was approved, expected to incur $55 million to $65 million in non-recurring charges in 2026 and 2027, aiming for $120 million in annualized cost savings.
• The voluntary suspension of Byte aligner sales in October 2024 and cessation of new patient offerings in January 2025 materially impacted results, with Byte sales representing approximately 2% of annual revenue in 2025.
• The company entered into new non-exclusive distribution agreements with Patterson Dental Holdings for dental equipment in the United States.
• R&D expenses decreased to $150 million (4.1% of net sales) in 2025, but the company plans to increase annual investment to at least 5% of net sales beginning in 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to declining sales, a substantial net loss, reduced cash flow from operations, and the elimination of dividends, despite some improvements in net loss compared to the prior year and the closure of the SEC investigation.

Positives

• Net loss improved to $598 million in 2025 from $910 million in 2024, primarily due to lower impairment charges.
• The SEC's Division of Enforcement concluded its investigation of the company and does not intend to recommend any enforcement action.
• Internal control over financial reporting was deemed effective as of December 31, 2025, remediating previously reported material weaknesses.
• Wellspect Healthcare segment net sales increased on a constant currency basis due to higher volumes and new product launches.
• Orthodontic and Implant Solutions segment adjusted operating income increased by 35.0%, driven by favorable adjustments for customer refunds and lower costs, despite lower sales.

Negatives

• Total net sales decreased by 3.0% (4.3% constant currency) to $3,680 million in 2025.
• The company reported a net loss of $598 million and a diluted loss per share of $3.00 for 2025.
• Cash flow from operations decreased significantly to $235 million in 2025 from $461 million in 2024.
• Goodwill and intangible asset impairment charges amounted to $650 million in 2025, including a full impairment of remaining goodwill in the Implant & Prosthetic Solutions reporting unit.
• Gross profit as a percentage of net sales decreased to 50.0% in 2025 from 51.6% in 2024, due to unfavorable product mix, pricing, and tariff costs.
• Interest expense, net, increased by 28.2% to $88 million in 2025, primarily due to a higher average carrying balance of total borrowings.
• The Board of Directors eliminated quarterly dividends on common stock starting in Q1 2026.
• The total net debt to total capitalization ratio increased to 59.9% at December 31, 2025, from 48.9% at December 31, 2024.
• The company continues to experience higher prices and supply chain disruptions for raw materials and wage inflation.
• The German Tax Investigation related to intercompany loans from 2016 and 2017 is ongoing, with potential adverse impacts on reputation and financial condition.

Risks

• Heavy reliance on information technology and cloud platforms (DS Core, Primescan 2) creates vulnerabilities to cyber incidents, data breaches, and AI-related cybersecurity risks.
• Evolving governmental oversight of personal information, cross-border data transfer restrictions, and AI technologies (e.g., EU AI Act, GDPR, HIPAA) may adversely affect business and incur significant compliance costs.
• Damage to the company's reputation or brand due to quality issues, customer dissatisfaction, or failure to innovate could negatively impact business.
• Inability to execute key strategic initiatives due to operational disruptions or competing priorities of distribution partners, potentially leading to financial losses and operational inefficiencies.
• Acquisitions, divestitures, or strategic investments may result in financial results different than expected and create integration challenges, higher operating expenses, or loss of key relationships.
• Failure to realize expected benefits from strategic initiatives, including restructuring plans (2024 Plan, 2026 Plan) and global ERP system implementation, could lead to business disruptions and higher costs.
• Inability to develop innovative products and solutions consistent with changing customer preferences and security requirements could lead to loss of market share and revenue.
• Ongoing business operations are susceptible to disruptions from extreme weather, natural disasters, epidemics, geopolitical conflicts (Russia-Ukraine, Middle East), worker strikes, and supply chain constraints, including reliance on single-source suppliers.
• The company may be required to recognize additional goodwill and indefinite-lived intangible asset impairment charges in the future due to market conditions or lower financial performance.
• Intellectual property may not adequately protect products, or products may infringe on third-party rights, leading to litigation, significant liabilities, or inability to commercialize products.
• Changes in credit ratings or macroeconomic impacts on credit markets may increase the cost of capital and limit financing options.
• Significant indebtedness could adversely affect financial condition, restrict strategic actions, and increase vulnerability to economic downturns.
• Foreign currency hedging and cash management transactions may be ineffective or only partially mitigate exchange rate fluctuations, exposing the company to unexpected volatility.
• Political or economic changes in global operations, including tariffs, trade policy changes (e.g., Chinese volume-based procurement), and geopolitical conflicts, could harm business and financial performance.
• Ongoing litigation and regulatory examinations, including securities class action lawsuits and derivative suits, could result in substantial costs, reputational harm, and significant damages.
• Inability to obtain necessary product approvals and marketing clearances from governmental authorities (e.g., FDA, EU MDR) could hinder product entry into the marketplace.
• Changes in tax rules or interpretations, operating structures, transfer pricing regulations, and ongoing tax investigations (e.g., German Tax Investigation, IRS audit) may harm business and adversely affect the effective tax rate.
• Inadequate levels of reimbursement from governmental or other third-party payors for procedures using products may cause revenue to decline.
• Challenges asserted against products due to real or perceived quality, health, or environmental issues (e.g., BPA in dental materials) could adversely affect brand, reputation, and operating results.
• Extensive, complex, and changing domestic and foreign laws and regulations (e.g., FCPA, anti-kickback, data privacy, environmental, climate disclosures) pose compliance risks and potential penalties.
• The market price for common stock may continue to be volatile due to various factors, including quarterly operating results and macroeconomic conditions.
• Certain provisions in governing documents and Delaware law may make it more difficult for a third party to acquire the company.
• Talent gaps and challenges in managing and retaining top talent may impact the ability to operate effectively and execute strategic initiatives.
• Inherent risk of legal actions, including product liability claims, antitrust suits, and employee benefit lawsuits, could result in substantial costs and harm the business.

Future Outlook

The company plans to increase its annual investment in research and development to approximately 5% of net sales beginning in 2026. Headwinds are expected to weigh on global growth in 2026 due to increasing uncertainties related to global trade policies and inflation. Capital expenditures are estimated to be in the range of $125 million to $150 million for the twelve months ending December 31, 2026, including investments for the new global ERP system, equipment upgrades, and capacity expansion. The 2026 restructuring plan is anticipated to result in approximately $120 million in annualized cost savings, with a portion to be reinvested in targeted return-to-growth initiatives. Management believes there is sufficient liquidity available for the next twelve months.

Management Comments

• "Our Companys mission is to transform oral health and continence care with innovative products, solutions and services through an engaged workforce."
• "We are shaping the future of dentistry while delivering meaningful value to customers and patients worldwide."
• "We believe our global talent strategy enables employees to perform at their highest potential in service of our customers."
• "The Company has a focus on maximizing operational excellence on a global basis."
• "The Company expects that the continued benefits from these global efficiency efforts will improve its cost structure in the long-term."
• "The Company intends to continue pursuing opportunities to expand the Companys product and solutions offerings, technologies, and sales and service infrastructure through partnerships."

Industry Context

StockSavvy.ai notes that the dental industry is expected to grow long-term due to increasing worldwide population, aging demographics, demand for aesthetic dentistry and clear aligners, opportunities in emerging markets, preference for single-visit dentistry, and increasing demand for digital collaboration and efficiency in dental offices, including the consolidation of dental practices into Dental Support Organizations (DSOs). The healthcare consumables market for urology and enterology products is also expected to grow due to aging demographics, chronic diseases, and expansion of medical insurance coverage. However, the company operates in highly competitive markets subject to rapid technological disruption and price competition. Macroeconomic conditions, including inflation, supply chain constraints, higher energy costs, labor shortages, and geopolitical tensions, are impacting consumer confidence and discretionary spending for elective procedures across the industry. The Chinese government's volume-based procurement process is also noted as a factor decreasing prices for medical devices and impacting margins.

Comparison to Industry Standards

• The company's historical R&D investment of approximately 4% of net sales is in line with industry standards for innovation-driven medical device companies, with a planned increase to 5% in 2026 indicating a strategic focus on maintaining competitiveness.
• The decline in CAD/CAM product volumes due to competitive pressures, particularly in the United States, suggests the company faces challenges in a segment where competitors may be offering lower price points or alternative solutions.
• The impact of tariffs and lower projected volumes on the Implant & Prosthetic Solutions reporting unit, leading to goodwill impairment, highlights the sensitivity of premium dental implant markets to economic conditions and competitive pricing, a common challenge for high-value medical device segments.
• The company's strategy to diversify its distributor base, particularly in the United States beginning in 2026, is a response to industry trends of dental practice consolidation and the growing significance of Dental Support Organizations (DSOs), which often seek more integrated and efficient supply chains.

Management Changes

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit filed in the U.S. District Court for the Eastern District of New York (EDNY Court) was settled in principle for $84 million in January 2025, with final approval by the EDNY Court on September 10, 2025. The company's net payment was $6 million after an offsetting insurance policy receivable.
• The Securities Litigation, a putative class action filed in the U.S. District Court for the Southern District of New York (SDNY Court) alleging materially false and misleading statements regarding revenue recognition and distributor rebate programs, was consolidated, and class certification was granted on July 10, 2025. Cross-motions for partial summary judgment were fully briefed on January 19, 2026.
• Several stockholder derivative suits (Presura, Snee, Manfre Derivative Litigations) with similar allegations to the Securities Litigation were consolidated and stayed by the Delaware Court of Chancery.
• The 2024 Securities Litigation, a consolidated putative class action in the SDNY Court alleging false and misleading statements regarding the Byte aligners business, had a motion to dismiss granted in part and denied in part on January 16, 2026.
• The OConnor Derivative Litigation and Andreotti Derivative Litigation, stockholder derivative suits with allegations similar to the 2024 Securities Litigation, were consolidated and stayed by the SDNY Court.
• A new stockholder derivative suit, the Chua Derivative Litigation, was filed on February 24, 2026, in the U.S. District Court for the Western District of North Carolina, alleging violations of federal securities laws and breach of fiduciary duties related to stock repurchases at artificially inflated prices.
• A claim filed by Mr. Carlo Gobbetti in the Milan Chamber of Arbitration seeking 28 million euros for alleged failure to pay a portion of a purchase price was rejected by the arbitral tribunal on July 22, 2024. Mr. Gobbetti appealed the ruling, and a final hearing for the appeal is scheduled for March 4, 2026.
• The IRS is conducting an examination of the company's U.S. federal income tax returns for tax years 2015 and 2016, with a proposed adjustment contested by the company through an administrative protest submitted in April 2024.
• The General Public Prosecutors Office Frankfurt am Main is conducting a criminal investigation related to intercompany loans implemented in 2016 and 2017, with no charges filed against the company or individuals as of the filing date.

Stakeholder Impact

• Shareholders: Negatively impacted by the elimination of quarterly dividends, significant net losses, and increased debt. The ongoing share repurchase program (with $1.2 billion remaining authorization) could provide future value, but no repurchases occurred in 2025. Stock price volatility is a continuing risk.
• Employees: Affected by restructuring plans (2024 and 2026 Plans) which involve headcount reductions but also aim for operational efficiency. Severance benefits are provided under the Key Employee Severance Benefits Plan. The company continues to invest in talent development, health & safety, and offers various benefit plans.
• Customers: New non-exclusive distribution agreements with Patterson Dental Holdings aim to enhance service and access to advanced technologies. Product innovation and clinical education initiatives are ongoing. However, tariffs and competitive pressures may impact product pricing and availability.
• Suppliers: The company faces risks related to supply chain disruptions and reliance on a limited number of single-source suppliers for raw materials, which could affect product manufacturing and delivery.
• Creditors: The company's increased total net debt and amendments to credit facility covenants indicate higher leverage, which could affect future borrowing costs and access to capital markets. However, the company was in compliance with all covenants at December 31, 2025.

Next Steps

• Increase annual investment in research and development to approximately 5% of net sales beginning in 2026.
• Incur non-recurring charges of $55 million to $65 million in 2026 and 2027 related to the 2026 restructuring plan.
• Reinvest a portion of the anticipated $120 million annualized cost savings from the 2026 Plan into targeted return-to-growth initiatives.
• Continue the multi-year implementation of a new global Enterprise Resource Planning (ERP) system.
• Monitor and evaluate the ongoing and potential impacts of tariffs and changes in trade policy on supply chain, costs, net sales, and profitability.
• Continue to monitor geopolitical conflicts and their potential impact on financial stability and operations.
• Continue to defend against the ongoing German Tax Investigation related to intercompany loans from 2016 and 2017.
• Proceed with cross-motions for partial summary judgment in the consolidated Securities Litigation in the SDNY Court.
• Attend the final hearing for the Milan Chamber of Arbitration appeal proceedings on March 4, 2026.
• Continue to contest the IRS's proposed adjustments for tax years 2015 and 2016 through an administrative protest with the IRS Independent Office of Appeals.
• Comply with California's enacted environmental laws related to climate disclosures in 2026.
• Evaluate the impact of new FASB ASUs on consolidated financial statements and disclosures.

Key Dates

Recommendation

The company reported a substantial net loss of $598 million, a decline in net sales, and a significant decrease in cash flow from operations for 2025. The elimination of quarterly dividends signals a need to conserve capital, which is a strong negative indicator for investors. While impairment charges were lower than the prior year, they remain substantial. The increased net debt to total capitalization ratio indicates higher financial risk. Furthermore, the company faces ongoing legal proceedings, a criminal tax investigation, and macroeconomic headwinds, all of which create significant uncertainty and potential future liabilities. Despite some strategic initiatives and R&D investments, the overall financial performance and outlook are concerning, warranting a strong sell recommendation for a seasoned investor.

Keywords

Dental products, Dental equipment, Healthcare consumables, SEC filing, 10-K, Financial results, Net loss, Net sales, Cash flow, Goodwill impairment, Intangible assets, Restructuring, Dividend, Debt, Cybersecurity, AI, Regulatory compliance, Litigation, Tax investigation, Global operations, Supply chain, R&D, Dentsply Sirona